Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
COYA 
Coya Therapeutics, Inc. Common Stock (COYA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: COYA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $16.64
1 Year Target Price $16.64
| 4 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -42.43% | Avg. Invested days 31 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 101.19M USD | Price to earnings Ratio - | 1Y Target Price 16.64 |
Price to earnings Ratio - | 1Y Target Price 16.64 | ||
Volume (30-day avg) 5 | Beta 0.27 | 52 Weeks Range 4.65 - 10.24 | Updated Date 09/14/2025 |
52 Weeks Range 4.65 - 10.24 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.24 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -3920.47% |
Management Effectiveness
Return on Assets (TTM) -38.53% | Return on Equity (TTM) -63.99% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 71429412 | Price to Sales(TTM) 238.96 |
Enterprise Value 71429412 | Price to Sales(TTM) 238.96 | ||
Enterprise Value to Revenue 168.68 | Enterprise Value to EBITDA -6.21 | Shares Outstanding 16725100 | Shares Floating 12631952 |
Shares Outstanding 16725100 | Shares Floating 12631952 | ||
Percent Insiders 7.12 | Percent Institutions 27.02 |
Upturn AI SWOT
Coya Therapeutics, Inc. Common Stock
Company Overview
History and Background
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies for neurodegenerative diseases, with an emphasis on regulatory T cells (Tregs). It was founded to leverage the therapeutic potential of Tregs in modifying disease progression.
Core Business Areas
- Treg-based therapeutics: Development of Treg-based therapies for neurodegenerative diseases like ALS and Alzheimer's.
- Clinical Development: Conducting clinical trials to evaluate the safety and efficacy of its lead Treg product candidates.
- Intellectual Property: Building a strong intellectual property portfolio around its Treg platform technology.
Leadership and Structure
Coya Therapeutics is led by a management team with experience in biotechnology and clinical development. The organizational structure includes departments focused on research, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- COYA 101: COYA 101 is Coya's lead product candidate, an autologous Treg cell therapy in clinical development for Amyotrophic Lateral Sclerosis (ALS). Market share is currently N/A as the product is still in clinical trials. Competitors include Biogen (Tofersen), Amylyx Pharmaceuticals (Relyvrio), and other companies developing ALS treatments.
- COYA 102: COYA 102 is another Treg cell therapy in development by Coya, targeting neurodegenerative diseases such as Alzheimer's. Market share is currently N/A as the product is still in clinical trials. Competitors include Eisai/Biogen (Lecanemab), Eli Lilly (Donanemab), and other companies developing Alzheimer's treatments.
Market Dynamics
Industry Overview
The biotechnology industry is highly competitive, characterized by rapid technological advancements, intense research and development efforts, and stringent regulatory oversight. There is a growing focus on personalized medicine and cell-based therapies.
Positioning
Coya Therapeutics is positioned as a company specializing in Treg-based therapies for neurodegenerative diseases. Its competitive advantage lies in its proprietary Treg platform and its focus on addressing unmet needs in these areas.
Total Addressable Market (TAM)
The TAM for ALS and Alzheimer's treatments is estimated to be billions of dollars annually. Coya is positioning itself to capture a portion of this market by developing innovative Treg-based therapies.
Upturn SWOT Analysis
Strengths
- Proprietary Treg platform technology
- Experienced management team
- Focus on unmet medical needs in neurodegenerative diseases
- Early clinical data showing promise
Weaknesses
- Limited financial resources
- Clinical trial risks and uncertainties
- Dependence on key personnel
- No approved products on the market
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion of Treg platform to other diseases
- FDA approval and commercialization of products
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
- Patent disputes
Competitors and Market Share
Key Competitors
- BIIB
- AMLY
- LLY
- ESALY
Competitive Landscape
Coya faces competition from established pharmaceutical companies with larger resources and approved products. Coya's advantage lies in its novel Treg approach and focus on specific neurodegenerative diseases.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by preclinical and early-stage clinical development activities.
Future Projections: Future growth projections depend on successful clinical trials, regulatory approvals, and commercialization of products. Analyst estimates vary depending on the perceived probability of success.
Recent Initiatives: Recent strategic initiatives include advancing COYA 101 and COYA 102 through clinical trials and exploring partnerships.
Summary
Coya Therapeutics is a promising but high-risk biotech company focused on Treg-based therapies. Its lead product candidates show potential, but clinical trial success is critical. The company needs to secure additional funding and navigate regulatory hurdles effectively. Overall rating is weak as it currently has no proven or FDA approved product and relies on future results for success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on your own research and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Coya Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters Houston, TX, United States | ||
IPO Launch date 2022-12-29 | CEO & Director Dr. Arun Swaminathan Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://coyatherapeutics.com |
Full time employees 8 | Website https://coyatherapeutics.com | ||
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary therapies to enhance the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease (AD), and Parkinson's disease. In addition, the company's pre-clinical product candidates include COYA 301, a low-dose interleukin 2 product candidate to treat AD; COYA 303, an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist for the treatment of inflammatory diseases; COYA 201, an antigen directed Treg-derived exosome product candidate to treat neurodegenerative, autoimmune, and metabolic diseases; COYA 206, an antigen directed Treg-derived exosome product candidate; and COYA 101. It has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. Coya Therapeutics, Inc. was founded in 2020 and is headquartered in Houston, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.